Trial Profile
The Impact of CCR5 Inhibitor Treatment Intensification on CD4+ T-Cell Recovery and Gene Expression Profiles in HIV-Infected Patients With Viral Suppression.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics; Pharmacogenomic
- 31 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jun 2011 Planned end date changed from 1 Jul 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.
- 21 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.